Methadone Maintenance for Prisoners

NCT ID: NCT00378079

Last Updated: 2014-04-03

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

211 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-09-30

Study Completion Date

2008-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This five-year study examines the benefits of methadone maintenance treatment initiated in prison and continued in the community to male offenders who were previously, but not currently, heroin-dependent. It is anticipated that such prisoners will have more favorable outcomes in the year following release with regard to drug abuse, crime, and HIV risk behavior than either prisoners who receive counseling only or begin initiation of methadone maintenance in the community

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Most prisoners with histories of pre-incarceration heroin addiction do not receive treatment while incarcerated or upon release. Effective treatment for such prisoners is urgently needed because rapid relapse typically follows release. Relapse is associated with increased risk for HIV, overdose death, criminal activity, and reincarceration. Other than three studies of methadone maintenance with short-term jail inmates, the only study of longer-term inmates who were previously, but not currently, heroin-dependent was the investigator's pilot study with pre-release inmates. Based on that pilot study, which found that initiating maintenance treatment is feasible and facilitates post-release treatment entry, the present study provides a more rigorous examination of this unique treatment approach.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heroin Addiction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

3

Group Type EXPERIMENTAL

Counseling + Methadone

Intervention Type DRUG

Counseling and methadone maintenance in prison, with opportunity to continue that treatment upon release

1

Group Type ACTIVE_COMPARATOR

Counseling Only

Intervention Type OTHER

Counseling only in prison, with passive referral to drug abuse treatment upon release

2

Group Type EXPERIMENTAL

Counseling + Transfer

Intervention Type DRUG

Counseling only in prison, with opportunity to enter methadone maintenance upon release

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Counseling Only

Counseling only in prison, with passive referral to drug abuse treatment upon release

Intervention Type OTHER

Counseling + Transfer

Counseling only in prison, with opportunity to enter methadone maintenance upon release

Intervention Type DRUG

Counseling + Methadone

Counseling and methadone maintenance in prison, with opportunity to continue that treatment upon release

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Heroin dependence in the year prior to current incarceration
* 3-6 months left to serve in prison-male pre-release inmate suitability for methadone maintenance as determined by medical evaluation
* Willingness to enroll in methadone maintenance
* Having a Baltimore address

Exclusion Criteria

* Pending parole hearing
* Pending charges
* Kidney failure
* Liver failure
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role collaborator

Friends Research Institute, Inc.

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Timothy W Kinlock, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Friends Research Institute, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Metropolitan Transition Center

Baltimore, Maryland, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Kinlock TW, Schwartz RP, Gordon MS. The significance of interagency collaboration in developing opioid agonist programs for inmates. Corrections Compendium 30(3)6-9,28-30,2005.

Reference Type BACKGROUND

Kinlock TW, Gordon MS, Schwartz RP, O'Grady K, Fitzgerald TT, Wilson M. A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug Alcohol Depend. 2007 Dec 1;91(2-3):220-7. doi: 10.1016/j.drugalcdep.2007.05.022. Epub 2007 Jul 12.

Reference Type RESULT
PMID: 17628351 (View on PubMed)

Kinlock TW, Gordon MS, Schwartz RP, O'Grady KE. A Study of Methadone Maintenance For Male Prisoners: 3-Month Postrelease Outcomes. Crim Justice Behav. 2008;35(1):34-47. doi: 10.1177/0093854807309111.

Reference Type RESULT
PMID: 18612373 (View on PubMed)

Gordon MS, Kinlock TW, Schwartz RP, O'Grady KE. A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction. 2008 Aug;103(8):1333-42. doi: 10.1111/j.1360-0443.2008.002238.x.

Reference Type RESULT
PMID: 18855822 (View on PubMed)

Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O'Grady KE. A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. J Subst Abuse Treat. 2009 Oct;37(3):277-85. doi: 10.1016/j.jsat.2009.03.002. Epub 2009 Mar 31.

Reference Type RESULT
PMID: 19339140 (View on PubMed)

Wilson ME, Kinlock TW, Gordon MS, O'Grady KE, Schwartz RP. Postprison release HIV-risk behaviors in a randomized trial of methadone treatment for prisoners. Am J Addict. 2012 Sep-Oct;21(5):476-87. doi: 10.1111/j.1521-0391.2012.00250.x.

Reference Type RESULT
PMID: 22882399 (View on PubMed)

Kinlock TW, Gordon MS, Schwartz RP, O'Grady KE. Individual Patient and Program Factors Related to Prison and Community Treatment Completion in Prison-Initiated Methadone Maintenance Treatment. J Offender Rehabil. 2013 Oct;52(8):509-528. doi: 10.1080/10509674.2013.782936.

Reference Type RESULT
PMID: 25580067 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01DA016237

Identifier Type: NIH

Identifier Source: secondary_id

View Link

1R01DA016237-03

Identifier Type: NIH

Identifier Source: org_study_id

View Link

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Treatment for Opioid Dependent Offenders
NCT01082679 COMPLETED PHASE2/PHASE3